Traitement de l’urticaire chronique par omalizumab : données en vie réelle

A. Hamelin(Sorbonne Université), A. Soria(Inserm), O. Bayrou, C. Pecquet(Ludwig Cancer Research), A. Barbaud(Sorbonne Université), P. Mathelier‐Fusade(Sorbonne Université), E. Amsler(Sorbonne Université)
Annales de Dermatologie et de Vénéréologie
January 1, 2019
10.1016/j.annder.2018.07.031
Cited by 2

Related Papers

The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria
|Allergy|2018|1.5k
The <scp>EAACI</scp>/<scp>GA</scp><sup>2</sup><scp>LEN</scp>/<scp>EDF</scp>/<scp>WAO</scp> Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update
|Allergy|2014|1.2k
The EAACI/GA2LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update
|Dermatology Review|2015|429
The definition, diagnostic testing, and management of chronic inducible urticarias - The EAACI/GA<sup>2</sup>LEN/EDF/UNEV consensus recommendations 2016 update and revision
|Allergy|2016|357
The definition and diagnostic testing of physical and cholinergic urticarias – EAACI/GA<sup>2</sup>LEN/EDF/UNEV consensus panel recommendations
|Allergy|2009|162